Fig. 12
From: Application of lipid nanovesicle drug delivery system in cancer immunotherapy
Reprint with permission from [120]. Copyright 2020, Elsevier Ltd
a Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. b The statistic of tumoral bioluminescence and c survival rate in vivo (n = 8, i.v., 5 mg OXA/kg, ~ 108 exosomes per mouse). d Statistical results of M1/M2 ratio (n = 3). Statistical results of (e) mature DCs, (f) CD8+T cells, and (e) Treg cells in orthotopic PANC-02 tumor-bearing mice after various treatments analyzed by flow cytometry. Data presented as means ± SD, one-way ANOVA, *p < 0.05, ***p < 0.001, ****p < 0.0001. (Groups: 1. PBS; 2. GEM; 3.OXA; 4. Scrbl-iEXO; 5. iEXO; 6. EXO-OXA; 7. iEXO-OXA).